GT719 universal cell injection for adults with relapsed or refractory CD19-positive B-cell cancers

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

This trial will test whether GT719, a universal CD19-targeting cell injection, is safe and can induce remissions in adults with relapsed or refractory CD19-positive B-cell lymphoma or B-cell acute lymphoblastic leukemia.

Quick facts

• Phase: Early Phase 1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Grit Biotechnology (Industry-sponsored)
• Drugs / interventions: Pembrolizumab, CAR-T, cyclophosphamide, fludarabine
• Locations: 1 site (Ganzhou, Jiangxi)
• Trial ID: NCT07131254 on ClinicalTrials.gov

What this trial studies

This is a prospective, single-arm, open-label early Phase 1 trial with dose-escalation and expansion cohorts enrolling up to 34 adults with relapsed or refractory CD19-positive B-NHL or B-ALL. Eligible participants are 18–75 years old with confirmed CD19 positivity, ECOG performance status 0–1, expected survival >12 weeks, and must meet prior-therapy washout requirements. Participants will receive GT719 injections and be followed for safety, anti-tumor activity, and cellular pharmacokinetics according to the protocol. The trial is sponsored by Grit Biotechnology and conducted at Ganzhou City People's Hospital in Jiangxi, China.

Who should consider this trial

Good fit: Adults aged 18–75 with relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma or B-ALL, ECOG 0–1, expected survival >12 weeks, and who meet washout requirements for prior therapies.

Not a fit: Patients with CD19-negative tumors, poor performance status (ECOG >1), very limited life expectancy, uncontrolled infections, or other serious comorbidities are unlikely to benefit.

Why it matters

Potential benefit: If successful, GT719 could provide a new off-the-shelf CD19-targeted cell therapy option for patients who have relapsed after, or are not candidates for, existing autologous CAR-T treatments.

How similar studies have performed: Autologous CD19-directed CAR-T therapies have achieved high remission rates in similar populations, while universal/allogeneic CD19 cell approaches are newer with promising but still early clinical evidence.

Eligibility criteria

Inclusion Criteria:

* 1\. Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
* 2\. Aged 18 to 75 years (inclusive), regardless of gender.
* 3\. Participants with refractory or relapsed acute B-cell lymphoblastic leukemia or B-cell lymphoma diagnosed according to the WHO 2016 classification.
* 4\. CD19 positivity confirmed by flow cytometry and/or histopathology.
* 5\. Eastern Collaborative Oncology Group (ECOG) physical fitness status score of 0 or 1.
* 6\. Expected survival period \> 12 weeks;
* 7\. For any prior systemic therapy (excluding immune checkpoint inhibitors), at least 2 weeks or 5 half-lives (whichever is shorter) must have elapsed before the participant is scheduled to receive the study treatment. For any prior treatment with immune checkpoint inhibitors (such as anti-PD-1 or anti-PD-L1 monoclonal antibodies like Pembrolizumab, OX40 agonists, 4-1BB agonists, etc.), at least 3 half-lives or 28 days (whichever is shorter) must have passed before the participant is scheduled to receive the study treatment.
* 8\. Toxicities caused by prior treatments must be stable and resolved to grade ≤ 1, excluding clinically insignificant toxicities such as alopecia.
* 9\. Have adequate renal, hepatic, pulmonary, and cardiac functions, defined as follows:

  1. . Creatinine Clearance (estimated by the Cockcroft-Gault formula) ≥ 60 mL/min;
  2. . Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 times the Upper Limit of Normal (ULN);
  3. . Total bilirubin ≤ 1.5 mg/dl, excluding participants with Gilbert syndrome;
  4. . Cardiac ejection fraction ≥ 50%, no signs of pericardial effusion detected by Echocardiography (ECHO), and no clinically significant abnormalities found on Electrocardiogram (ECG);
  5. . No clinically significant pleural effusion;
  6. . Baseline oxygen saturation \> 92% when measured under room air conditions.
* 10\. Female participants of childbearing potential must have a negative result from a serum or urine pregnancy test. Females who have undergone surgical sterilization or been postmenopausal for at least 2 years are not considered to be of childbearing potential. They must agree to use highly effective and reliable contraceptive methods for 1 year after receiving the study treatment, and are strictly prohibited from donating oocytes within 1 year after the infusion of the study treatment during the study period.
* 11\. Male participants who have active sexual life with females of childbearing potential must agree to use highly effective and reliable contraceptive methods for 1 year after receiving the study treatment. All male participants are strictly prohibited from donating sperm within 1 year after the infusion of the study treatment during the study period.

Exclusion Criteria:

* 1\. Participants with a history of central nervous system (CNS) leukemia/lymphoma, or those with CNS leukemia/lymphoma shown by magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT) intracranial imaging during the screening period, or those with detected malignant cells in cerebrospinal fluid or brain metastases.
* 2\. History of testicular leukemia/lymphoma, and imaging examinations during the screening period suggest active testicular leukemia/lymphoma.
* 3\. History of other untreated malignant tumors within the past 5 years or concurrent with the current disease, excluding adequately treated carcinoma in situ of the cervix, localized cutaneous squamous cell carcinoma, basal cell carcinoma, localized prostate cancer, ductal carcinoma in situ of the breast, or ≤T1 urothelial carcinoma. Participants with prostate cancer undergoing active surveillance are eligible for this study;
* 4\. Hematopoietic stem cell transplantation with curative intent performed within 6 weeks prior to the planned infusion of GT719 cells;
* 5\. For participants with a history of hematopoietic stem cell transplantation, ≤6 months have elapsed since they received allogeneic hematopoietic stem cell transplantation;
* 6\. History of CD19 CAR-T/NK therapy (except for participants who have received GT719 and are eligible for retreatment);
* 7\. Received systemic glucocorticoid drugs within 7 days before cell infusion, except inhaled glucocorticoids.
* 8\. History of allergic reactions to any components of the drugs intended for use in the study (including but not limited to the study drug GT719 cell infusion preparation, cyclophosphamide, and fludarabine).
* 9\. Presence or suspicion of uncontrolled fungal, bacterial, viral, or other infections, or infections requiring management with intravenous (IV) antimicrobial agents;
* 10\. Positive results for any of the following tests: Human Immunodeficiency Virus (HIV) antibody, Treponema pallidum antibody, Cytomegalovirus (CMV) IgM, Epstein-Barr Virus (EBV) IgM;
* 11\. Active hepatitis B and/or active hepatitis C (HCV RNA positive); participants who are positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (anti-HBc) but with HBV-DNA levels within the normal range may be included;
* 12\. Presence of any indwelling lines or drainage catheters (e.g., percutaneous nephrostomy tubes, indwelling Foley catheters, biliary drainage tubes, or pleural/peritoneal/pericardial catheters). Dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are permitted;
* 13\. Presence or history of central nervous system (CNS) disorders, such as seizures, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving the CNS;
* 14\. Participants with lymphoma involvement of the cardiac atria or ventricles.
* 15\. Presence of any of the following within 6 months prior to signing the informed consent form: uncontrolled congestive heart failure (New York Heart Association Class III-IV, see Appendix III), angina pectoris, myocardial infarction, cardiomyopathy, stroke (excluding lacunar infarction), coronary/peripheral artery bypass surgery, clinically significant arrhythmias (as judged by the investigator) including but not limited to ventricular arrhythmias, significantly prolonged QT interval (QTc ≥500 ms corrected by the Bazett's method, as specifically judged by the investigator), poorly controlled hypertension (systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg), poorly controlled diabetes mellitus, pulmonary embolism, diffuse pulmonary lesions, impaired pulmonary function, or any medical condition deemed by the investigator to be unsuitable for participation in this clinical study;
* 16\. Participants for whom urgent treatment is expected or likely to be required within 6 weeks due to ongoing or impending tumor emergencies (e.g., tumor mass effect, tumor lysis syndrome);
* 17\. Primary immunodeficiency.
* 18\. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy;
* 19\. Any medical condition that may interfere with the assessment of the safety or efficacy of the study treatment;
* 20\. Vaccination with live attenuated vaccines or mRNA vaccines within 8 weeks prior to lymphodepleting conditioning, or inactivated vaccines within 4 weeks prior;
* 21\. Females of childbearing potential who are pregnant or breastfeeding. Females who have undergone sterilization surgery or been postmenopausal for at least 2 years are not considered to be of childbearing potential;
* 22\. Male and female participants who are unwilling to use contraception from the time of informed consent until 6 months after the completion of treatment.
* 23\. Participants who, in the judgment of the investigator, are unlikely to complete all protocol-required study visits or procedures, including follow-up, or to comply with the requirements of study participation;
* 24\. History of autoimmune diseases within the past 2 years that have caused end-organ damage or required systemic immunosuppressive agents/systemic disease-modifying agents (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus).

Where this trial is running

Ganzhou, Jiangxi

• Ganzhou City People's Hospital — Ganzhou, Jiangxi, China (Recruiting)

Study contacts

• Study coordinator: Hongsheng Zhou

Conditions Hematological Malignancy